Form 4 for MLTX MoonLake Immunotherapeutics
Accepted 2026-01-09 00:00:00 ET · period of report 2026-01-07 · accession 0001213900-26-002907 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-09 | 2026-01-07 | MLTX | Bodenstedt Matthias | CFO | A - Grant | $0.00 | +354.3K | 1.28M | +38% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A ordinary shares, par value $0.0001 per share | 2026-01-07 | A | A | 354,296 | $0.00 | 1,276,305 | D | — | — |